Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
PT Bundamedik Tbk (BMHS.JK)
Jakarta Pusat, ID
Operating as a key healthcare provider in Indonesia, PT Bundamedik Tbk (also known as PT Bunda Medik) had a significant footprint as of December 31, 2021. Its facilities included two maternal and child hospitals, three general hospitals, two clinics, ten specialized in-vitro fertilization (IVF) centers, and fourteen diagnostic laboratories. Beyond its direct medical services, the company diversified into the distribution of pharmaceuticals and medical equipment, alongside interests in the hotel industry, medical tourism, and management consulting. Established in 1973, PT Bundamedik Tbk is headquartered in Jakarta Pusat, Indonesia, and operates as a subsidiary of PT Bunda Investama Indonesia.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.11% | -3.78% | -4.30% | -7.77% | +5.95% | -7.29% | -25.83% | -53.16% | -58.02% | -58.02% | -58.02% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2025-08 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Care Facilities: +10.2%+3.8% Q1'26: -2.1% (vs Q1'25)
-
EPS growth Medical - Care Facilities: +19.2%+19.4% ★ Q1'26: -98.0% (vs Q1'25)
-
FCF margin FCF growth · Medical - Care Facilities: +32.0%+2.0% ★ Q1'26: -10.4% (vs Q1'25)
-
EBIT margin Medical - Care Facilities: +11.3%+7.1% Q1'26: +4.4% (vs Q1'25)
-
ROIC Medical - Care Facilities: +6.8%+2.6% Q1'26: +1.6% (vs Q1'25)
-
Share dilution Medical - Care Facilities: +0.0%-13.3% ★ Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Care Facilities: 0.99×5.65× Q1'26: 7.95× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
1.71T
est: 1.75T (-2.3%)
|
1.66T
est: 1.67T (-0.7%)
|
1.49T
est: 1.55T (-4.0%)
|
1.55T
est: 1.55T (+0.1%)
|
1.61T
est: 1.70T (-5.0%)
|
1.88T
1.88T – 1.88T
+10.5% YoY
|
2.08T
2.08T – 2.08T
+11.0% YoY
|
| EBITDA |
570.28B
est: 366.15B (+55.7%)
|
344.13B
est: 349.49B (-1.5%)
|
203.45B
est: 298.65B (-31.9%)
|
212.48B
est: 299.05B (-28.9%)
|
239.90B
est: 327.16B (-26.7%)
|
361.63B
361.63B – 361.63B
+10.5% YoY
|
401.30B
401.30B – 401.30B
+11.0% YoY
|
| EBIT |
485.15B
est: 250.37B (+93.8%)
|
223.91B
est: 238.98B (-6.3%)
|
89.89B
est: 190.44B (-52.8%)
|
98.78B
est: 190.69B (-48.2%)
|
115.29B
est: 208.62B (-44.7%)
|
230.60B
230.60B – 230.60B
+10.5% YoY
|
255.89B
255.89B – 255.89B
+11.0% YoY
|
| Net Income |
315.36B
est: 238.23B (+32.4%)
|
128.93B
est: 109.26B (+18.0%)
|
7.46B
|
11.94B
est: 28.35B (-57.9%)
|
12.42B
est: 21.64B (-42.6%)
|
31.34B
31.34B – 31.34B
+44.8% YoY
|
41.78B
41.78B – 41.78B
+33.3% YoY
|
| SGA |
163.39B
est: 260.74B (-37.3%)
|
188.29B
est: 248.87B (-24.3%)
|
463.17B
est: 298.62B (+55.1%)
|
198.87B
est: 299.02B (-33.5%)
|
507.80B
est: 327.13B (+55.2%)
|
361.60B
361.60B – 361.60B
+10.5% YoY
|
401.26B
401.26B – 401.26B
+11.0% YoY
|
| EPS |
36.66
est: 27.69 (+32.4%)
|
14.99
est: 12.70 (+18.0%)
|
0.87
|
1.39
est: 3.80 (-63.4%)
|
1.66
est: 2.90 (-42.8%)
|
4.20
4.20 – 4.20
+44.8% YoY
|
5.60
5.60 – 5.60
+33.3% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-22 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-21 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-20 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-19 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-18 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-13 | B | 3/5 | 5/5 | 3/5 | 3/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-12 | B | 3/5 | 5/5 | 3/5 | 3/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-11 | B | 3/5 | 5/5 | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-08 | B | 3/5 | 5/5 | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-07 | B | 3/5 | 5/5 | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-06 | B | 3/5 | 5/5 | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-05 | B | 3/5 | 5/5 | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-04 | B | 3/5 | 5/5 | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-30 | B | 3/5 | 5/5 | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-29 | B | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-28 | B | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-27 | B | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-24 | B | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-23 | B | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | B | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-21 | B | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | B | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | B | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | B | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-15 | B | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Agus Heru Darjono | President Director | — | male |
| Emilia Rouli Simatupang | Director of Human Capital & Director | — | female |
| Josephine Tobing | Corporate Secretary | — | female |
| Tubagus Adi Satria Prakasa | Head of Internal Audit & Risk Management Unit | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for BMHS.JK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
